Walter P. Carney

Andover Eye Associates — United States

Medicine · Health Sciences

36h-index4.5kcitations128works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(47), Monoclonal and Polyclonal Antibodies Research(40), Peptidase Inhibition and Analysis(22), Cancer Treatment and Pharmacology(18), Cancer-related Molecular Pathways(12)

Publications128 total

Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis
Frontiers in Immunology·2023· 56 citedOpen Access
Abstract P4-10-25: Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer
Cancer Research·2020· 7 cited
Abstract 126: Multidimensional gene expression models for characterizing response and metastasis in solid tumor samples
Tumor Biology·2019Open Access
Abstract 126: Multidimensional gene expression models for characterizing response and metastasis in solid tumor samples
Cancer Research·2019
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)
Breast Cancer Research and Treatment·2017· 23 cited
Abstract P3-06-14: Serum activin A and response to the aromatase inhibibitor (AI) letrozole versus tamoxifen in metastatic breast cancer
Cancer Research·2015
Abstract 4332: Diagnostic applications of fatty acid synthase monoclonal antibodies
Cancer Research·2014
Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31.
Journal of Clinical Oncology·2014
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831
Cancer·2013· 49 cited
Elevated pretreatment serum biomarkers and correlation with progression-free (PFS) and overall survival (OS) in first-line trastuzumab-treated metastatic breast cancer.
Journal of Clinical Oncology·2013
A Bayesian meta-analysis of the prognostic value of circulating HER2/neu levels in breast cancer (BC) patients.
Journal of Clinical Oncology·2013
Abstract 5108: Capture and enumeration of mesenchymal CTCs on the OnQChip platform.
Cancer Research·2013
Plasma MN (carbonic anhydrase IX) and outcome in sunitinib-treated metastatic renal cell cancer.
Journal of Clinical Oncology·2013· 1 cited
Pretreatment serum biomarkers and clinical outcome in the phase II trial of zibotentan (endothelin A receptor antagonist) in metastatic CRPC.
Journal of Clinical Oncology·2013
Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?
Biomarkers in Cancer·2013· 52 citedOpen Access
Microfluidics and Circulating Tumor Cells
Journal of Molecular Diagnostics·2012· 210 citedOpen Access
Detecting and classifying circulating tumor cell subclasses from On-Q-ity microfluidic chips using a customized imaging platform.
Journal of Clinical Oncology·2012
Abstract 2389: A microfluidic system for the selection of circulating tumor cells that utilizes both affinity and size capture technologies
Cancer Research·2012· 3 cited
Pretreatment serum biomarkers and clinical outcome in the phase II trial of zibotentan (endothelin A receptor antagonist) in metastatic CRPC.
Journal of Clinical Oncology·2012· 2 cited
Abstract 2276: Serum endoglin and uPA change predicts PFS and overall survival in first line trastuzumab-treated breast cancer
Cancer Research·2011
page 1 of 7Next →

Frequent Co-authors

Allan Lipton(13), Suhail M. Ali(13), Kim Leitzel(9), Paul W. Brandt‐Rauf(9), Peter Hamer(7), Laurence M. Demers(6), M. S. Hirsch(5), Steven J. Smith(5), Rainer Neumann(4), Harold A. Harvey(4), Hilary A. Chaudri‐Ross(4), Dean B. Evans(4), V. R. Iacoviello(4), Kim Leitzel(4), Sheryl Brown‐Shimer(4), Jiin-Chyuan Luo(3), Immaculata De Vivo(3), Karen Pierce(3), R H Rubin(2), R. A. Hoffman(2)